📋 Tender Overview
Grant agreement ID: 101286165
DOI
10.3030/101286165
EC signature date
18 March 2026
Start date
1 June 2026
End date
30 November 2028
Description: The EIC-funded REVOLV project will introduce a pioneering industrial bioprinting platform designed to create complex human tissues with unprecedented speed and precision. By utilising volumetric printing technology, the system avoids the slow, layer-by-layer approach of traditional methods, producing functional biological constructs in under ten seconds. The platform will integrate artificial intelligence with human-derived resins to ensure that results are both reproducible and compliant with medical safety standards. This approach focuses on providing scalable solutions for pharmaceutical research specifically aimed at improving drug-testing accuracy while reducing the need for animal trials. Ultimately, REVOLV seeks to establish a standardised, automated ecosystem that accelerates the development of regenerative medicine and safer therapeutic treatments.
Objective
REVOLV will deliver the first industrial-grade volumetric bioprinting platform, combining AI-driven precision, GMP-compliant human-derived resins, and seamless microplate automation. This next-generation system achieves ultra-fast (<10s per construct), contact-free production of complex, functional tissues while maintaining cell viability above 90%. This innovation addresses long-standing limitations of conventional bioprinting, as slow layer-by-layer deposition, poor reproducibility, and limited vascularization, transforming volumetric bioprinting into a scalable solution for pharmaceutical R&D, toxicology, and regenerative medicine.
To achieve this breakthrough, REVOLV combines advanced hardware, novel biomaterials, and a rigorous validation pathway. The platform integrates AI-powered calibration to guarantee reproducible, high-fidelity printing across diverse geometries and resins, while newly developed human-derived supramolecular resins ensure both regulatory alignment and biological performance. These innovations will be validated through functional liver constructs produced in microplate format, directly demonstrating relevance for pharmaceutical workflows. Alongside the technical development, the consortium will establish a clear route to commercialization and regulatory acceptance, ensuring that the system is not only scientifically robust but also ready for large-scale adoption.
REVOLV will achieve TRL 6 by demonstrating system integration in pharma-like environments, anchoring a commercialization pathway led by Readily3D SA with strong contributions from UMC Utrecht and INsociety. The outcome will be a GMP-ready, automated, and animal-free 3D bioprinting ecosystem that reduces reliance on animal testing, strengthens European leadership in advanced manufacturing, and accelerates safer, more predictive drug development worldwide.
